
pharmaceutical benefits. In addition, a need continues to exist in the medical arts for orally deliverable forms of such compounds.

SUMMARY

The present disclosure provides compounds that can be NMDA modulators, for example, partial agonists of NMDA. More specifically, the present disclosure provides a compound having the formula:




(I),

or a stereoisomer, an N-oxide, and/or a pharmaceutically acceptable salt thereof, where R^b is selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, and C_1-C_6 alkyl; R^1 is selected from the group consisting of hydrogen, halogen, and C_1-C_6 alkyl; and R^2 is selected from the group consisting of hydrogen, halogen, and C_1-C_6 alkyl.

Also provided herein are pharmaceutical compositions including a disclosed compound; and a pharmaceutically acceptable excipient. Such a composition can be suitable for oral or intravenous administration to a patient.

In some embodiments, the compounds described herein bind to NMDA receptor subtypes. In some embodiments, the compounds described herein bind to one subtype and not another.

In one aspect of the present disclosure, there is provided a compound having the formula:




or a stereoisomer, an N-oxide, and/or a pharmaceutically acceptable salt thereof.

In another aspect of the present disclosure, there is provided a pharmaceutical composition comprising the compound disclosed herein; and a pharmaceutically acceptable excipient.

The present disclosure also provides a method of treating a condition selected from the group consisting of autism, anxiety, depression, bipolar disorder, attention deficit disorder, attention deficit hyperactivity disorder (ADHD), schizophrenia, a psychotic disorder, a psychotic symptom, social withdrawal, obsessive-compulsive disorder, phobia, post-traumatic stress syndrome, a behavior disorder, an impulse control disorder, a substance abuse disorder, a sleep disorder, a memory disorder, a learning disorder, urinary incontinence, multiple system atrophy, progressive supra-nuclear palsy, Friedrich's ataxia, Down’s syndrome, fragile X syndrome, tuberous sclerosis, olivio-ponto-cerebellar atrophy, cerebral palsy, drug-induced optic neuritis,


What is claimed is:

1. A compound having the formula:




or a stereoisomer, an N-oxide, and/or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 having the formula:



or an N-oxide and/or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 having the formula:



or an N-oxide or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising the compound of claim 1; and a pharmaceutically acceptable excipient.

5. The pharmaceutical composition of claim 4, suitable for oral administration.

6. The pharmaceutical composition of claim 4, suitable for intravenous, intranasal, subcutaneous, and/or sublingual administration.